Essential Principles of Safety and Performance: Article 5.2

1. Key takeaways

Article 5.2.1 of RTS 11.03.02:21 sets six essential principles of safety and performance for manufacturers, items a to f. Design and production must ensure the device is safe for its intended use and does not compromise the clinical condition of the patient or the health of the user; risk assessment must be carried out and risks reduced at the design, production and use stages; the device must perform as claimed under normal conditions of use; performance and safety must not deteriorate during the service life to a degree that affects the patient or user; performance and safety must not be affected by transport, packaging and storage where the manufacturer’s instructions are followed; and known or foreseeable risks must be weighed against the benefit of the intended use. Article 5.2.2 makes this the manufacturer’s responsibility and allows the authority to verify the evidence before or after market entry.

The principles are drafted as outcomes, not as procedures, which is why each one can be matched to a specific document in the registration file. That correspondence is the practical value of Article 5.2.1.

• Six principles apply cumulatively, from design through service life.
• Risk must be reduced at three stages: design, production and use.
• Performance is measured against the manufacturer’s own claims.
• Transport, packaging and storage are treated as safety variables, not logistics details.
• Acceptability is a balance of risk against benefit, not the absence of risk.

2. Legal basis

Article 5.2.1 is expressed as principle, and Article 6.3.2 converts it into evidence. The table links each limb to the provision through which it reaches the dossier, together with the reference framework cited in Article 8.1.

3. Expert insights

Insight one: the six principles are not declaratory, because each has a counterpart in the dossier. Every limb of Article 5.2.1 can be traced to a document required under Article 6.3.2. The risk assessment in item b) corresponds to the risk management report under Article 6.3.2.1 k); the requirement that performance not deteriorate over service life in item d) corresponds to the technical documentation on shelf life under Article 6.3.2.5 c); the transport and storage condition in item e) corresponds to storage and transport conditions under Article 6.3.2.5 d). A reviewer can therefore call for material by letter of the alphabet, which makes an index built on a to f the most efficient structure a file can have.

Insight two: the responsible party is the manufacturer, not the registration holder. Article 5.2.2 opens by stating that ensuring conformity with the essential principles is the responsibility of the manufacturer. Where a Chinese manufacturer works with a local registration partner in El Salvador, that responsibility cannot be transferred by contract: an agreement can allocate costs and cooperation duties, but conformity remains with the manufacturer. Language in a distribution or holding agreement that implies otherwise does not alter the position under the regulation and may create a false sense of protection on both sides.

Insight three: verification may occur before or after market entry. Article 5.2.2 states that the authority may verify conformity evidence before or after the device is placed on the market, using the manufacturer’s technical documentation, a sanitary inspection or any assessment it considers necessary. The exposure is therefore not limited to a refused registration; a product already on the market can be examined on the same principles, and an inspection finding can carry consequences that a refusal at the desk would not.

Insight four: acceptability is judged as risk against benefit, not as zero risk. Article 5.2.1 f) requires known and foreseeable risks to be weighed against the benefit of the intended use. That leaves room for high-risk devices: a Clase D product does not have to demonstrate the absence of risk, but must show that risks have been identified, reduced and remain proportionate to the benefit. The reasoning closes the loop with the risk management report required by Article 6.3.2.1 k), which is where the balance has to be argued in writing.

Insight five: Article 8.1 anchors the six principles in an international reference framework. Among the references listed in Article 8.1 is the WHO 2017 global model framework for medical device regulation, which places the wording of Article 5.2.1 within a structure used across jurisdictions. That matters for a manufacturer that already holds approvals elsewhere, because the same six outcomes can be described using documentation it already maintains. It does not, however, convert foreign approval into local conformity: Article 5.2.2 still allows the authority to verify the evidence itself, before or after market entry, and the file has to stand on its own terms when that verification happens.

4. Practical recommendations

• Index the file against items a to f of Article 5.2.1 and note the page of the corresponding material for each, so that both the receiving desk and the reviewer can locate it.
• Prepare the risk management report on an ISO 14971 structure and state the conclusion on residual risk against benefit explicitly.
• Support items d) and e) with validation documents on shelf life, storage and transport rather than a single sentence of assurance.
• State in the contract that conformity responsibility rests with the manufacturer, so the registration partner does not assume that responsibility moves with the certificate.
• Keep the original conformity evidence available for post-market verification, including superseded versions where the current version refers to them.
• For Clase C and Clase D products, give the benefit argument its own section instead of mentioning it inside the risk report.

5. Verification checklist

• □ The file is indexed against the six principles a to f
• □ The risk management report states residual risk and benefit conclusions
• □ Shelf life, storage and transport validation documents are complete
• □ The contract states that conformity responsibility rests with the manufacturer
• □ Original conformity evidence is archived and retrievable
• □ Clase C and Clase D products carry a separate benefit argument section

Instruments cited: RTS 11.03.02:21, Dispositivos Médicos. Requisitos para la Regulación Sanitaria de Dispositivos Médicos (Acuerdo No. 14-2022, Diario Oficial No. 156, Tomo No. 436, 2022-08-23), Articles 5.2.1, 5.2.2, 6.3.2.1 k), 6.3.2.5 c) and d), and 8.1.

Regulatory information verified as at 29 October 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Salvadoran market. Our team manages Ministry of Health (MINSAL) sanitary registration applications, prepares Spanish-language dossiers, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com